Centers for the Development of Medications to Treat Drug Dependence

The summary for the Centers for the Development of Medications to Treat Drug Dependence grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Centers for the Development of Medications to Treat Drug Dependence: The purpose of this RFA is to solicit applications for funding research centers called Medication Development Units (MDUs) directed towards the identification, evaluation and development of safe and effective medications for the treatment of cocaine, methamphetamine, club drug, opiate, and cannabis related disorders, including substance use (abuse and dependence) and substance-induced disorders such as substance withdrawal and intoxication. The applicants must have demonstrated the capability to conduct full-scale single site clinical trials (placebo-controlled (PC) or active controlled (AC), double-blind (DB)) using the proposed therapeutic approach. Applicants opting to propose multisite trials must have adequately demonstrated efficacy in a single site PC/AC, DB trial. Such applicants must also demonstrate the ability to affiliate rapidly with other sites (through subcontract or collaborative mechanisms) to launch a multisite Phase II or Phase III PC/AC, DB trial. Under this RFA, applicants may focus on human laboratory studies on medication interactions with other drugs; pharmacokinetic or pharmacodynamic studies, Phase I safety/tolerability or Phase II or III clinical efficacy studies; or, if justified, multisite efficacy studies. Research may focus on both currently approved and/or novel, investigational medications. Because the treatment of cocaine, methamphetamine, opiate, or cannabis related disorders necessitates a multidisciplinary approach, optimal pharmacological treatments require a behavioral treatment strategy. Therefore, applications may propose the concurrent evaluation of pharmacotherapy and behavioral treatment approaches in an integrated design, whereby behavioral treatment components should provide a platform for the medication trials proposed. Study designs should be of adequate size and well controlled. Proposals for the treatment of opiate dependence will only be considered if they address unmet clinical needs in this treatment area (i.e., non-opiate agonist medications, medications to treat opiate-dependent individuals who have not responded well to currently available medications, or the treatment of special populations such as opiate-dependent pregnant women and adolescents).